Replies to post #256448 on Biotech Values

[DewDiligence]

PFE acquires small-molecule GLP-1 from China’s Fosun Pharma:

https://www.businesswire.com/news/home/20251209536063/en/Pfizer-Enters-into-Exclusive-Collaboration-and-License-Agreement-with-YaoPharma

Under the terms of the agreement, YaoPharma [a wholly owned subsidiary of Fosun Pharma] will complete an ongoing YP05002 Phase 1 clinical trial and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide.

YaoPharma will receive an upfront payment of $150 million and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.935 billion, as well as tiered royalties on sales, if approved.

Pfizer plans to conduct combination studies of YP05002 with its glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist PF-07976016 currently in Phase 2 development and with other small molecules in its pipeline.

[DewDiligence]

PFE reports phase-2b data_for_lead Metsera drug, a long-acting GLP-1 agonist:

https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial

• VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3.

• Study met primary endpoint of statistically significant weight reduction at 28 weeks with a competitive tolerability profile [but see details below—Dew].

• Weight loss continued after pre-planned switch from weekly to monthly dosing, with no plateau observed at 28 weeks.

• 10 Phase 3 trials with PF’3944 expected to advance in 2026; expansive clinical development program underway with 20+ planned and ongoing studies across diverse obesity pipeline.

At week 28, 10% and 12.3% placebo-adjusted weight loss was achieved in Arms 1 and 3 respectively, which are the low and medium monthly maintenance dosing regimens planned for inclusion in Phase 3. These data show robust and continuous weight loss after switching to monthly dosing, with no plateau observed at week 28, suggesting continued weight loss is expected as the study continues through week 64.

… Across Arms 1 and 3, five total participants discontinued from treatment due to adverse events in the weekly phase and five total participants discontinued from treatment due to AEs in the monthly phase [i.e. 10 discontinuations all told from these trial arms]. There were zero discontinuations from treatment due to AEs in the placebo group.

The full dataset will be presented at the ADA conference on 6/6/26.